newsfilter
← Latest News
GlobeNewswire·

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq